Becky L. Phan
YOU?
Author Swipe
View article: 4CPS-349 Role of hospital pharmacists in oncogeriatric consultations: a retrospective study
4CPS-349 Role of hospital pharmacists in oncogeriatric consultations: a retrospective study Open
Background and importance Population aging and the growing risk of developing cancer with age lead to an increasing number of elderly patients treated in the oncology care unit. Elderly people are fragile, polypathological and polymedicate…
View article: Letter: tofacitinib use for biologic‐refractory paediatric inflammatory bowel disease
Letter: tofacitinib use for biologic‐refractory paediatric inflammatory bowel disease Open
LINKED CONTENT This article is linked to Ma et al paper. To view this article, visit https://doi.org/10.1111/apt.15297 .
View article: Real World Experience With Ustekinumab in Children and Young Adults at a Tertiary Care Pediatric Inflammatory Bowel Disease Center
Real World Experience With Ustekinumab in Children and Young Adults at a Tertiary Care Pediatric Inflammatory Bowel Disease Center Open
Background: Ustekinumab is an effective therapy for Crohn disease currently approved for adults. Off‐label use in the pediatric population is increasing, but its effectiveness in this age group has not been reported. Aims: The aim of the s…
View article: Higher Trough Vedolizumab Concentrations During Maintenance Therapy are Associated With Corticosteroid-Free Remission in Inflammatory Bowel Disease
Higher Trough Vedolizumab Concentrations During Maintenance Therapy are Associated With Corticosteroid-Free Remission in Inflammatory Bowel Disease Open
Background and Aims Vedolizumab is an anti-α4β7 biologic approved for ulcerative colitis [UC] and Crohn’s disease [CD]. We aimed to examine the association of maintenance vedolizumab concentrations with remission. Methods We performed a cr…
View article: Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease
Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease Open
Our results suggest that vedolizumab is efficacious and safe in pediatric IBD patients, with UC patients experiencing earlier and higher rates of remission than CD patients. Anti-TNF-naive patients experienced higher remission rates than t…